Active Pass Pharmaceuticals Alters Management Composition.Business Editors/Health/Medical Writers BIOWIRE2K VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 22, 2003 Active Pass Pharmaceuticals announces that Rod Campbell is leaving his position as Chief Financial Officer to pursue other opportunities. Concurrent with Mr. Campbell's departure, Active Pass is pleased to announce that Jeff Tomlinson has been appointed Chief Business Officer. Commenting on the changes, President & Chief Executive Officer Peter B. Reiner stated, "We appreciate the contribution that Rod has made to the growth of our company, and wish him well in his future endeavors. At the same time, we are delighted to have Jeff join our Senior Management team, bringing with him extensive experience gleaned from his years in major pharma, biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. , and venture capital." Jeff Tomlinson began his professional career at SmithKline Beecham in 1994 where he held a variety of positions both in the United Kingdom and in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . In 1999 he joined Gene Logic of Gaithersburg, Maryland, where he was Director of Strategic Marketing and Business Development. In 2001 he moved to GrowthWorks Capital in Vancouver, where he was Vice President of Investments. About Active Pass Active Pass is a privately held biotechnology company developing drugs that target ABC ABC in full American Broadcasting Co. Major U.S. television network. It began when the expanding national radio network NBC split into the separate Red and Blue networks in 1928. transporters, a valuable class of targets for diseases with substantial markets. Our gene-family approach to drug discovery enables us to profile compounds for potency, specificity and bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration. bi·o·a·vail·a·bil·i·ty n. , identifying those compounds most likely to survive the rigors of drug development. Moreover, our balanced portfolio of therapeutic programs, including age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. , travelers' diarrhea trav·el·ers' diarrhea or trav·el·er's diarrhea n. Diarrhea and abdominal cramps occurring among travelers to regions where sanitation is poor, commonly caused by a toxin-producing strain of the bacterium Escherichia coli. , and lipid disorders, provides multiple opportunities for success. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion